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Abstract
Background: High-sensitivity troponin I (hs-TnI) and troponin T (hs-TnT) are moderately correlated and independently
related to outcome in atrial fibrillation (AF). Rate controlling therapy has been shown to reduce hs-TnT, however the
potential impact on hs-TnI levels, and whether this differs from the effects on hs-TnT, has not been investigated
previously.
Methods: Sixty patients with stable, permanent AF without heart failure or known ischemic heart disease were
included in a randomised crossover study (mean age 71 ± 9 years, 18 women). Diltiazem 360 mg, verapamil 240 mg,
metoprolol 100 mg, and carvedilol 25 mg were administered once daily for three weeks, in a randomised sequence.
At baseline and on the last day of each treatment period, hs-TnI was measured at rest and after a maximal exercise test
and compared to hs-TnT.
Results: Hs-TnI and hs-TnT correlated moderately at baseline (rs = 0.582, p < 0.001). All drugs reduced both the resting
and the peak exercise levels of hs-TnI compared with baseline (p < 0.001 for all). The decline in resting hs-TnI and hs-TnT
values relative to baseline levels was similar for all drugs except for verapamil, which reduced hs-TnI more than hs-TnT
(p = 0.017). Levels of hs-TnI increased significantly in response to exercise testing at baseline and at all treatment regimens
(p < 0.001 for all). The relative exercise-induced increase in hs-TnI was significantly larger compared to hs-TnT at baseline
(p < 0.001), on diltiazem (p < 0.001) and on verapamil (p = 0.001).
Conclusions: In our population of stable, permanent AF patients, all four rate control drug regimens reduced hs-TnI
significantly, both at rest and during exercise. The decline in hs-TnI and hs-TnT levels associated with beta-blocker and
calcium channel blocker treatment was similar, except for a larger relative decrease in hs-TnI levels following verapamil
treatment.
Trial registration: www.clinicaltrials.gov (NCT00313157).
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Background
Atrial fibrillation (AF) confers an independent risk for
stroke and death [1, 2]. High-sensitivity cardiac troponin
assays permit measurements of very low levels of circulat-
ing troponins, and have revealed a low-level, chronic tropo-
nin release in AF populations [3–5]. Minor elevations in
cardiac troponins below the 99th percentile upper reference
limit are associated with cardiovascular morbidity and
mortality in AF [6–9], and persistent elevations indicate
worse prognosis than transient elevations [10]. As cardiac
troponins emerge as a prognostic biomarker in AF, it is of
paramount importance to recognise the factors influencing
on troponin levels. An imminent and unsolved issue is to
what extent the different treatment modalities in AF are
capable of modulating cardiac troponin levels.
In the Rate Control in Atrial Fibrillation (RATAF) study,
beta-blockers and calcium channel blockers reduced high-
sensitivity troponin T (hs-TnT) levels significantly [11],
supporting evidence of an association between heart rate
and troponin levels in AF [12]. The RATAF study also
revealed an exercise-induced increase in hs-TnT levels
[11]. A rise in cardiac troponins in response to exercise
testing has been demonstrated in patients without evi-
dence of myocardial ischemia [13, 14], suggesting alterna-
tive mechanisms for troponin release other than cardiac
cell death.
High-sensitivity troponin assays have revealed differ-
ences in sensitivity and specificity between high-sensitivity
troponin I (hs-TnI) and hs-TnT with potential clinical
implications [15, 16]. The two molecules appear to be only
moderately correlated in AF, with hs-TnI being more asso-
ciated with cardiovascular diseases and AF burden, and
hs-TnT with age, male sex and diabetes [17]. These obser-
vations indicate that factors influencing low-level, chronic
troponin elevation may differ between hs-TnI and hs-
TnT. At present, it is unknown whether rate control ther-
apy and exercise testing in an AF population affect the
two troponin subtypes differently.
Accordingly, the objectives of the present study of pa-
tients with permanent AF were first to assess the impact
of four rate-reducing drugs on hs-TnI levels at rest and
after a maximal exercise test using a high-sensitivity assay
and second to compare the results with those obtained
using a high-sensitivity assay for troponin T.
Methods
Study design
The present study was a substudy of the RATAF study, in
which four different once-daily drug regimens for rate
control in permanent AF were compared in a prospective,
randomised, investigator-blind, crossover study [18]. A
flow-chart of the study is presented in Fig. 1. Briefly,
patients age >18 years with stable, permanent AF without
heart failure (clinical or radiological signs of congestive
heart failure and/or reduced ejection fraction) or known
ischemic heart disease were included. Patients who were
treated with rate-reducing drugs at the time of inclusion
had a wash-out period of two weeks before baseline
evaluation was performed. The patients on digitalis
were instructed to discontinue this drug, and did not
start the wash-out period until digitalis was undetect-
able in serum. After baseline evaluation, the partici-
pants were randomised through a computer-generated
block randomisation list to receive all of the following
drug regimens for at least three weeks in a randomised
cross-over design: (I) metoprolol slow-release tablets
100 mg o.d. (AstraZeneca), (II) diltiazem sustained release
capsules 360 mg o.d. (Pfizer), (III) verapamil modified
release tablets 240 mg o.d. (Abbott), and (IV) carvedilol
immediate release tablets 25 mg o.d. (Roche/HEXAL).
The patients were randomised from May 2006 to June
2010. The investigator was blinded with regard to study
drug sequence, whereas for practical reasons the partici-
pants were aware of the drug assigned. Compliance of the
drug regimen was assessed by pill count after each drug
period. Before starting the first treatment, and on the last
day of each treatment period, serum samples were collected
at rest, at peak exercise and 15 min after exercise termin-
ation. The RATAF study was approved by the Regional
Ethics Committee and the Norwegian Medicines Agency,
Fig. 1 Flow chart of the study. HR, heart rate; n, number of patients; SR,
sinus rhythm
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and all patients signed informed consent in accordance
with the Helsinki
Declaration. The RATAF study was registered at
www.clinicaltrials.gov (NCT00313157) at 10th of April
2006.
Baseline evaluations
All patients underwent clinical examination before entering
the study. Left ventricular systolic function was assessed
with echocardiography. Echocardiographic measurements
were averaged over five cardiac cycles, if possible in a phase
with close to normal heart rate and relative regular R-R
intervals. Lung function was assessed by spirometry and
diffusing capacity.
Exercise test
The cardiopulmonary exercise tests were performed
on a bicycle ergometer (Ergoline 800, Bitz, Germany)
in accordance with American College of Cardiology/
American Heart Association guidelines [19]. Details have
been published previously [20]. The expected peak oxygen
uptake was calculated for each patient. Individual proto-
cols were chosen based on age, gender and weight, with
the aim of reaching each patient’s estimated maximal per-
formance in 8 to 12 min. The patients were tested with
their individual protocol every time, preferably on the
same time of the day. Oxygen consumption, carbon diox-
ide production, and respiratory exchange ratios were mea-
sured continuously during exercise by an automated gas
exchange system (Vmax Spectra, SensorMedics, CA,
USA). Patients were encouraged to maintain a pedaling
rate of at least 60 per minute and continue until exhaus-
tion. A physician and a technician blinded to the patients’
treatment were present during all tests.
Arrhythmia-related symptoms
Arrhythmia-related symptoms were assessed using a self-
administered questionnaire: The symptom Checklist—
Freqency and Severity (SCL) in Norwegian translation
[21, 22]. The SCL questionnaire rates the frequency
(from 0 to 4) and severity (from 1 to 3) of 16 symp-
toms potentially associated with AF, with higher scores
representing worse symptoms.
Troponin levels
Blood samples for hs-TnI and hs-TnT analysis were drawn
after 30 min of rest in the supine position before the exer-
cise test, at peak exercise and 15 min after exercise
termination. Serum was prepared within one hour by cen-
trifugation at 2000 x g for 15 min at room temperature.
Aliquots were then stored at −70 °C and later analysed in
one batch. The samples had been through one freeze-
thaw cycle before the analyses of hs-TnT and two
freeze-thaw cycles before the analyses of hs-TnI. In
patient samples, cardiac troponins are reported to be
stable at −70 °C and through repeated freeze-thaw cy-
cles [23–25].
Hs-TnI levels were determined using the ARCHI-
TECTSTAT high sensitive troponin I assay (Abbott
Laboratories, Abbott Park, Illinois, USA), with a limit
of blank of 0.7 ng/L, a limit of detection of 1.2 ng/L
and a limit of quantification of 5.0 ng/L. The coeffi-
cients of variation in our laboratory were 11.7 % for
hs-TnI = 2.5 ng/L, 6.4 % for hs-TnI = 28.5 ng/L and
5.2 % for hs-TnI = 178.1 ng/L. The 99th percentile
upper reference limit for healthy individuals is 23 ng/L for
the entire reference population (36 ng/L in men and
15 ng/L in women) [26].
Results with regard to hs-TnT and N-terminal pro-
B-type natriuretic peptide (NT-proBNP) have been
published previously, and are included in this article
as reference [11, 20]. Hs-TnT levels were analysed on
the Cobas e411 analyser using the Roche high sensi-
tive Troponin T assay (Roche Diagnostics, Basel,
Switzerland) with a limit of blank of 3.0 ng/L, a limit
of detection of 5.0 ng/L and a limit of quantification
of 13.0 ng/L. The coefficients of variation in our la-
boratory were 5.0 % for hs-TnT = 13.1 ng/L, 5.5 % for
hs-TnT = 30.4 ng/L and 1.4 % for hs-TnT = 85.2 ng/L.
The 99th percentile upper reference limit for the entire
reference population is 14 ng/L (15 ng/L in men and
10 ng/L in women) [27]. NT-proBNP was assessed using
the Elecsys proBNP sandwich immunoassay on an Elecsys
2010 (Roche Diagnostics, Basel, Switzerland).
Statistical analysis
Categorical variables are given as frequencies (%) and
continuous variables are given as mean ± standard devi-
ation (SD) for normally distributed variables, whereas
median (25th percentile,75th percentile) is given for var-
iables not normally distributed. P-values from multiple
comparisons between treatments were Bonferroni ad-
justed. Group comparisons of continuous variables
were tested by Student t test or the Mann–Whitney U-
test depending on distribution. Categorical data were
compared by the chi-square test or Fischer’s exact test
where appropriate. The impact of continuous clinical
variables on hs-TnI and hs-TnT was analysed using
Spearman correlation coefficient, denoted rs. Variables
associated with logarithmically transformed hs-TnI and
hs-TnT were examined using univariate and multivari-
ate linear regression analysis. Variables related to tropo-
nin levels with a p-value of <0.10 in univariate analyses
were included in a multivariate regression model. Medi-
cations at randomisation were not included as they
were thought only to reflect the disease that indicated
their use. Wilcoxon signed-rank test was used to com-
pare hs-TnI levels at rest and at peak exercise. The
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different treatment regimens (including baseline with
no drug intervention) were compared using a linear
mixed model for repeated measurements, with a ran-
dom intercept for each patient. Possible carryover ef-
fects were assessed with an interaction term between
treatment regimens and time periods. As this inter-
action term was not statistically significant, it was
removed from the final statistical model. Spearman cor-
relation coefficient was used to examine correlations
between hs-TnI and hs-TnT, and a two way scatterplot
with a fitted ordinary least-squares regression line was
used. Troponin values were logarithmically transformed
before entered into the mixed model and the linear re-
gression model. A two-sided p-value of <0.05 was con-
sidered statistically significant. Statistical analyses were
performed with IBM SPSS Statistics for Windows, ver-
sion 21.0 (IBM Corp., New York, USA).
Results
Baseline characteristics of the 60 participants that com-
pleted the study are given in Table 1. Hs-TnI was de-
tectable in all patients. Four of the patients (7 %) had
levels above the sex-specific 99th percentile of a healthy
reference population (36 ng/L in men and 15 ng/L in
women). The median (25th percentile, 75th percentile)
hs-TnI level at rest was 5.2 (3.8, 8.5) ng/L at baseline
(no treatment), 4.5 (3.3, 5.9) ng/L during treatment
with diltiazem, 4.1 (2.8, 5.6) ng/L on verapamil, 4.5 (3.0,
6.0) ng/L on carvedilol and 4.1 (2.7, 6.2) ng/L on meto-
prolol (Table 2, Fig. 2). Resting hs-TnI levels did not
correlate to gender. We found no associations between
baseline levels of hs-TnI and the presence of comorbid-
ities like hypertension, diabetes mellitus, renal impair-
ment, stroke or chronic obstructive pulmonary disease.
Hs-TnI did neither correlate to NT-proBNP levels nor
CHA2DS2-VASc score, which is a measure of stroke
risk in patients with atrial fibrillation, with scores
ranging from 0 to 9 and higher scores indicating
greater risk. NT-proBNP correlated to baseline hs-
TnT (rs = 0.331, p < 0.001). In multivariate analysis, older
age was associated with higher hs-TnT levels (p = 0.006)
[11], whereas no association was found between age and
hs-TnI.
All drug regimens reduced the resting and the peak
exercise levels of hs-TnI compared to baseline (p < 0.001
for all; values are given in Table 2 and Fig. 2), with no
significant differences between the treatments. Resting
hs-TnI and hs-TnT values decreased equally relative to
baseline levels, except for verapamil, which reduced hs-
TnI more than hs-TnT (p = 0.017) (Table 3, Fig. 3). The
relative reduction in resting hs-TnI levels did neither
correlate to the relative change in resting heart rate nor
the relative change in systolic blood pressure. There
were no significant correlations between hs-TnI values
and symptom severity or frequency, assessed by the
SCL questionnaire.
Levels of hs-TnI increased significantly by exercise
testing, both at baseline and with all treatments (p < 0.001
Table 1 Baseline characteristics
Variable N = 60
Age, years 71 ± 9
Gender, female/male 18/42
BMI, kg/m2 27 ± 4
Duration of permanent atrial fibrillation, months 11 (2–121)
CHA2DS2-VASc score 2.3 ± 1.5
Hypertension 25 (42 %)
Stroke or transient ischemic attack 7 (12 %)
Diabetes Mellitus 3 (5 %)
Chronic obstructive pulmonary disease 3 (5 %)
Current cigarette smoking 3 (5 %)
Alcohol intake, units/week 3.5 (0–35)
Systolic blood pressure, mm Hg 141 ± 18
Diastolic blood pressure, mm Hg 91 ± 10
Heart rate at rest, beats per minute 95 ± 15
Left atrial diameter, long-axis view, mm 50.4 ± 6.6
Left ventricular ejection fraction, % 61.4 ± 7.5
Forced expiratory volume in one second, Liter 2.75 ± 0.83
Forced expiratory volume in one second, % predicted 94.6 ± 16.8
Diffusion capacity of the lung for carbon monoxide,
% predicted
87.3 ± 17.3
Hemoglobin, g/dl 14.6 ± 1.2
Estimated glomerular filtration rate, mL/min 77.1 ± 17.6
NT-proBNP, pg/mL 1039 ± 636
Medication
Warfarin 56 (93 %)
Aspirin 4 (7 %)
Angiotensin receptor blocker or angiotensin-converting
enzyme inhibitor
22 (37 %)
Diuretics 9 (15 %)
Statins 12 (20 %)
Rate controlling medication at study entry, before wash-out
period
Metoprolol 34 (57 %)
Carvedilol 2 (3 %)
Verapamil 11 (18 %)
Diltiazem 1 (2 %)
Digitoxin 8 (13 %)
Values are expressed as mean ± SD, median (range) or frequencies (%).
Glomerular filtration rate is estimated from creatinine level, age and gender.
Abbreviations: CHA2DS2-VASc score is a measure of stroke risk in patients
with atrial fibrillation, with scores ranging from 0 to 9 and higher scores
indicating greater risk; NT-proBNP, N-terminal pro-B-type natriuretic peptide
SD standard deviation
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for all; values are given in Table 2). The relative
exercise-induced increase in hs-TnI was significantly
larger compared to hs-TnT at baseline (p < 0.001) and
at treatment with diltiazem (p < 0.001) and verapamil
(p = 0.001) (Table 4, Fig. 4). There were no significant
differences in exercise-induced increase between the two
troponin subunits during treatment with beta-blockers.
The relative exercise-induced increase in hs-TnI levels
was similar in men and in women.
The resting levels of hs-TnI and hs-TnT correlated
moderately at baseline and at all drug regimens; base-
line (rs = 0.582, p < 0.001) (Fig. 5), diltiazem (rs = 0.455,
p < 0.001), verapamil (rs = 0.454, p < 0.001), metoprolol
(rs = 0.382, p = 0.003) and carvedilol ((rs = 0.465, p < 0.001).
Discussion
In the present study of stable patients with permanent AF,
normal systolic function and no history of ischemic heart
disease, hs-TnI was detectable in all patients. All four rate-
controlling drugs reduced hs-TnI levels significantly both at
rest and during exercise. The decline in hs-TnI and hs-TnT
levels associated with beta-blocker and calcium channel
blocker treatment was similar, except for a larger relative
decrease in hs-TnI levels following verapamil treatment.
The relative exercise-induced increase in hs-TnI was larger
than for hs-TnT at baseline and during treatment with cal-
cium channel blockers.
A significant reduction in circulating levels of hs-TnI
at rest and at peak exercise was achieved with all four











Baseline 95 ± 15 141 ± 18 91 ± 10 5.2 (3.8, 8.5) 6.8 (4.5, 9.7)
Diltiazem 77 ± 13* 135 ± 13** 83 ± 9* 4.5 (3.3, 5.9)* 5.4 (3.9, 7.4)*
Verapamil 82 ± 16* 133 ± 15* 83 ± 9* 4.1 (2.8, 5.6)* 5.3 (3.7, 6.8)*
Metoprolol 81 ± 15* 135 ± 17** 86 ± 10** 4.1 (2.7, 6.2)* 5.2 (3.4, 6.9)*
Carvedilol 78 ± 11* 132 ± 19* 85 ± 10* 4.5 (3.0, 6.0)* 5.1 (3.8, 6.7)*
Values are expressed as mean ± SD or median (25th percentile, 75th percentile) depending on distribution
*p < 0.001 compared with baseline
**p ≤ 0.01 compared with baseline
bpm, beats per minute
hs-TnI, high-sensitivity troponin I
SD standard deviation
p<0.001 
Fig. 2 Resting hs-TnI levels at baseline and during treatments. All drug regimens reduced the resting levels of high-sensitivity troponin I compared to
baseline (p < 0.001 for all, p-values derived from the Wilcoxon signed-rank test). Center lines show the medians; box limits indicate the 25th and 75th
percentiles; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles. Abbreviations: hs-TnI, high-sensitivity troponin I
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rate-controlling drugs. Although the study drugs have
different pharmacodynamic profiles and effects on 24-h
heart rate [18], they had similar effects on hs-TnI
release. Previous published results from the RATAF
study demonstrated similar effects of the four treatments
on resting hs-TnT levels, except for a larger relative de-
crease in hs-TnI levels following verapamil treatment
[11]. A causal relationship between heart rate reduction
and subsequent lower levels of troponin has been sug-
gested as heart rate may predict troponin I levels in AF
patients [12]. However, a decreased systolic and diastolic
blood pressure has also been associated with lowered
levels of cardiac troponins in patients with essential
hypertension treated with the calcium channel blocker
amlodipine [28]. The changes in hs-TnI levels were not
significantly correlated to changes in heart rate in our
study, and this may indicate that other mechanisms than
heart rate reduction could be of relevance. In addition to
the potential effects of blood pressure reduction, pa-
tients with subclinical ischemic heart disease may have
benefited from the anti-ischemic abilities of the study
drugs. Hence, the mechanisms behind the attenuated
troponin release induced by rate-controlling drugs in
permanent AF need to be investigated further.




















to baseline level, %
Baseline 5.2 (3.8, 8.5) 10.0 (7.0, 13.0)
Diltiazem 4.5 (3.3, 5.9) 9.0 (7.0, 12.0) 0.14 (0.04, 0.30) 0.14 (0.0, 0.23) 14 % 14 %
Verapamil 4.1 (2.8, 5.6) 8.0 (6.0, 11.0) 0.24 (0.09, 0.41)* 0.18 (0.05, 0.25) 24 % 18 %
Metoprolol 4.1 (2.7, 6.2) 8.0 (6.0, 10.5) 0.18 (0.02, 0.33) 0.14 (0.0, 0.25) 18 % 14 %
Carvedilol 4.5 (3.0, 6.0) 8.0 (6.0, 12.0) 0.18 (0.01, 0.32) 0.13 (0.0, 0.20) 18 % 13 %
Values are expressed as median (25th percentile, 75th percentile). *p < 0.05 compared with hs-TnT
hs-TnI, high-sensitivity troponin I




Fig. 3 Relative decrease in hs-TnI and hs-TnT levels following treatment. The decline in hs-TnI and hs-TnT levels associated with beta-blocker and calcium
channel blocker treatment was similar, except for a larger relative decrease in hs-TnI levels following verapamil treatment (p = 0.017) (p-values derived from
the Mann–Whitney U-test). Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile
range from the 25th and 75th percentiles. Abbreviations: hs-TnI, high-sensitivity troponin I; hs-TnT, high-sensitivity troponin T
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The exercise-induced increase in hs-TnI was signifi-
cant with no differences between the treatments. The
relative exercise-induced increase in hs-TnI was sig-
nificantly larger compared to hs-TnT at baseline and
at treatment with calcium channel blockers. The discrep-
ancy could be due to assay properties, as the hs-TnI assay
has a lower limit of detection and quantification compared
to the hs-TnT assay. Other explanations could be that there
are differences in release kinetics between the two mole-
cules, or that the underlying mechanisms responsible for
exercise-induced troponin release affect the two subunits
differently. While even minor elevations of resting hs-TnT
and hs-TnI hold prognostic value in AF, the implications of
exercise-induced troponin release in subjects with AF are
unknown. A transient, exercise-induced troponin re-
lease has been documented in healthy individuals and
may represent a physiological response that does not
necessarily comprise any deleterious effects to the
healthy heart at all [29–31]. Changes in troponin con-
centrations during exercise stress testing may improve
Table 4 Hs-TnI and hs-TnT levels at peak exercise



















to resting level, %
Baseline 6.8 (4.5, 9.7) 11.0 (7.0, 14.0) 0.23 (0.14, 0.40)* 0.06 (−0.05, 0.13) 23 % 6 %
Diltiazem 5.4 (3.9, 7.4) 9.0 (7.0, 12.0) 0.23 (0.12, 0.32)* 0.11 (0.0, 0.19) 23 % 11 %
Verapamil 5.3 (3.7, 6.8) 9.0 (6.0, 12.0) 0.24 (0.10, 0.35)** 0.11 (0.0, 0.20) 24 % 11 %
Metoprolol 5.2 (3.4, 6.9) 9.0 (7.0, 12.0) 0.19 (0.09, 0.29) 0.12 (0.07, 0.22) 19 % 12 %
Carvedilol 5.1 (3.8, 6.7) 9.0 (7.0, 13.0) 0.16 (0.06, 0.27) 0.13 (0.04, 0.20) 16 % 13 %
Values are expressed as median (25th percentile, 75th percentile)
*p < 0.001 compared with hs-TnT
**p ≤ 0.01 compared with hs-TnT
hs-TnI, high-sensitivity troponin I














































Fig. 4 Relative exercise-induced increase in hs-TnI and hs-TnT levels. The relative exercise-induced increase in hs-TnI was significantly larger compared
to hs-TnT at baseline (p < 0.001) and at treatment with diltiazem (p < 0.001) and verapamil (p = 0.001) (p-values derived from the Mann–Whitney U-test).
Center lines show the medians; box limits indicate the 25th and 75th percentiles; whiskers extend 1.5 times the interquartile range from the 25th and
75th percentiles. Abbreviations: hs-TnI, high-sensitivity troponin I; hs-TnT, high-sensitivity troponin T
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diagnostic accuracy for detection of ischemia in pa-
tients with suspected coronary artery disease [32];
however, there are contradictory reports [13, 14].
The correlation between hs-TnI and hs-TnT in this study
was relatively moderate, in accordance with observations in
an AF cohort [17], and in a population with stable coronary
heart disease [15]. The mobilization of troponin T across
the cellular membrane of a cardiac myocyte could be atten-
uated by its larger size and higher molecular weight com-
pared to the smaller troponin I molecule, a proposal which
is supported by evidence of troponin I being more sensitive
in the setting of acute myocardial infarction [16]. The
relatively modest correlation between hs-TnI and hs-
TnT may as well be explained by discrepancies in assay
properties, permitted by the lack of harmonisation and
standardisation between different hs-TnI and hs-TnT
platforms [23, 26, 33].
Levels of NT-proBNP correlated with hs-TnT, but not
with hs-TnI. All drugs reduced the troponins similarly,
whereas beta-blockers increased NT-proBNP levels and
calcium channel blockers decreased NT-proBNP levels
[20]. The interpretation of elevated NT-proBNP levels in
AF is challenging as the arrhythmia itself is associated with
an increase in NT-proBNP, and significantly higher cut-off
levels are required to diagnose heart failure in AF patients
[34]. Heart failure with preserved ejection fraction is preva-
lent in AF populations [35, 36], and natriuretic peptides
may be useful in this setting [37]. However, a diagnosis of
diastolic dysfunction by echocardiography is more difficult
to make in AF due to the irregular heart rhythm and
inherent changes in mitral flow. Tissue Doppler measures
could have shed more light on the possible role of diastolic
dysfunction in our population; however, such data were not
available.
The value of high-sensitivity troponin assays in the clinic
is dependent on knowledge of the impact of confounding
factors like medications and exercise testing on troponin
levels. Interpretation of low-level chronic troponin eleva-
tions is a challenge for clinicians, and can only be relieved
by better understanding of the mechanisms and factors
influencing troponin release. In this perspective, the present
study extends the information provided by Ulimoen et al.
[11] by showing that rate-control and exercise testing
significantly influence hs-TnI levels in an AF population,
and that the effects on hs-TnI and hs-TnTare comparable.
Study limitations
Twenty patients did not fulfil all drug treatment periods
and were therefore not included in this analysis. How-
ever, these patients had similar baseline characteristics
as those who completed all parts of the study. Patients
with systolic heart failure were not included in the study;
however we have not conducted echocardiographic
assessment of diastolic function and cannot exclude the
possibility that some patients had heart failure with pre-
served ejection fraction. Ischemic heart disease was an
exclusion criterion in the present study, and we empha-
sise that our results may not be valid for such patients.
The available formulations of the study drugs differ with
Fig. 5 Scatterplot showing the association between baseline levels of logarithmically transformed hs-TnI and hs-TnT. Scatterplot with fitted linear
regression line and 95 % confidence interval curves. Regression coefficient was 0.35, 95 % CI (0.28, 0.42), p < 0.001, adjusted R2 0.24. Abbreviations:
hs-TnI, high-sensitivity troponin I; hs-TnT, high-sensitivity troponin T
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regard to pharmacokinetic profile, which may have influ-
enced exercise capacity and cardiac troponin levels.
Conclusions
In the present study of stable patients with permanent AF,
normal systolic function and no history of ischemic heart
disease, hs-TnI was detectable in all patients. All four rate-
controlling drugs reduced hs-TnI levels significantly both at
rest and during exercise. The decline in hs-TnI and hs-TnT
levels associated with beta-blocker and calcium channel
blocker treatment was similar, except for a larger relative
decrease in hs-TnI levels following verapamil treatment.
The relative increase in hs-TnI during exercise testing was
larger than for hs-TnT at baseline and during treatment
with calcium channel blockers.
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